UNSPSC 51102832: Chloramphenicol/hydrocortisone/polymyxin b

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP350. This VA Drug Class (OP350) classifies this compound as belonging to the group ANTI-INFECTIVE/ANTI-INFLAMMATORY COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51102832 Chloramphenicol/hydrocortisone/polymyxin b is a Commodity code, but the recent state and local opportunities tagged under it show little alignment with the code's nominal pharmaceutical ingredient scope — the actual solicitations involve naloxone procurement, first-aid medical supplies for emergency response, generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription program development. The code does not capture a coherent product or service line being actively solicited by state and local jurisdictions at present, and the mismatch between the code's chemical specificity and the broader pharmacy and medical-supply acquisitions tagged to it suggests this code may be incorrectly applied in practice or sees limited direct procurement activity tied to the specific compound itself.

The issuing bodies include a county health authority (Seminole County, Florida), a city fire department (Tampa Fire Department through City of Tampa Purchasing), a state health and human services agency (Texas HHS Commission), and a multistate cooperative purchasing vehicle (Minnesota MMCAP). Recent opportunities span Florida, Texas, and Minnesota, with the MMCAP procurement extending to Oregon participants. Representative solicitations include an IFB from Seminole County (IFB60459723LAS, due July 26, 2023) for naloxone and drug deactivation systems; an IFB from the City of Tampa (26P00145, due March 13, 2026) for medical and first-aid supplies budgeted at $700,000 and sheltered for certified Small Local Business Enterprises; an RFP from Minnesota MMCAP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating states; and an RFI from Texas HHS (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs. The code's weak connection to actual procurement activity warrants verification against issuing bodies' intended scope before pursuing opportunities tagged under it.